06/10/2024
Revolutionizing Tissue Analysis: Katana Labs' AI-Powered Cloud Platform for Multiplex Immuno-Fluorescence Image
Katana Labs advances tissue analysis with its web-based solution for multiplex immuno-fluorescence images!
The platform not only delivers stunning visualizations but also ensures precise whole-cell segmentation using advanced AI, offering unparalleled insights. In fields like cancer research, where tumor heterogeneity and spatial biology are critical, such tools become essential. The cloud platform offers seamless access to comprehensive intensity and shape feature extraction, enabling researchers to analyze complex mIF tissue data.
Unravel the intricacies of your multiplex immuno-fluorence images – directly from your web browser!
- Enjoy crystal clear visualization of highly multiplexed whole slide images.
- Leverage robust, AI-powered whole cell segmentation for unparalleled accuracy.
- Comprehensively extract intensity and shape features.
- All conveniently accessible in our cloud platform.
- Interested? Drop us a line for a demo: mail(ät)katana-labs.com
24/09/2024
Unlock the Power of Your IHC Images with Katana Labs' Stain Separation Tool
Katana Labs is proud to introduce our innovative stain separation tool, designed to streamline immunohistochemistry (IHC) analysis. Available directly in your web browser, this cutting-edge tool allows researchers to effortlessly split markers in brightfield IHC images with just a single click.
This solution promises to boost reproducibility, improve insights into biomarker expression, and increase efficiency in your research. Want to learn more? We’re offering live demos! Simply contact us to book your demo and experience the tool firsthand.
08/09/2024
Successful Business Roundtable in Berlin Paves Way for Future Collaborations Between Katana Labs and Saudi Arabia
A highly inspiring Business Roundtable took place in Berlin on 8th of September, marking a significant milestone in fostering international collaboration between Saxony’s thriving life sciences ecosystem and Saudi Arabia. Organized by biosaxony, the roundtable featured an esteemed Saudi Arabian delegation led by His Excellency Khalid bin Abdulaziz Al-Falih, Minister of Investment, and Her Excellency Sara Al Sayed, Deputy CEO of the Saudi Investment Promotion Authority.
The event brought together key stakeholders to explore future opportunities for investment, research, and development in the life sciences sector. One of the event’s notable participants was Katana Labs, represented by Falk Zakrzewski, showcasing the company’s innovative AI solutions for cancer diagnostics.
“It was an honor to be part of such an impactful event and to represent Katana Labs at this important meeting,” said Falk Zakrzewski. “Saxony’s world-class life sciences ecosystem, from cutting-edge research to groundbreaking companies and a robust clinical network, was on full display. This event laid the foundation for exciting future collaborations between our region and Saudi Arabia.”
20/08/2024
Katana Labs showcases its PAIKON platform for cancer diagnostics at the Medical AI Meetup Day in Dresden
Katana Labs a fantastic time at the 5th Meetup on AI in Medicine! An inspiring evening, where experts explored the transformative potential of AI in healthcare. Highlights included Sebastian Bodenstedt from National Center for Tumor Diseases Dresden (NCT/UCC) insights on AI’s role in surgical training, Martin Pentenrieder from IQONIC.AI deep dive into the balance between innovation and data privacy, our startup Katana Labs AI assistance PAIKON in cancer diagnostics for pathology as well as the presentation of IntelliLung project from Else Kröner Fresenius Center for Digital Health. Exciting discussions and networking underscored the critical importance of AI for all stakeholders in medicine.
Read more <<<here>>>
06/08/2024
Katana Labs provides insights into open foundation models for digital pathology
Katana Labs contributed to the writing of an article, exploring the transformative potential of open-source AI in cancer research. Their insights help highlight how collaborative efforts and freely available models are revolutionizing healthcare diagnostics and patient outcomes.
The article discusses the impact of the open-source movement on AI in healthcare, particularly in cancer research. Several companies, including PAIGE, Bio Optimus, Kaiko AI, Hist AI, and Microsoft Research, have released powerful open-source AI models. These models aim to enhance cancer diagnostics and patient outcomes, and are now freely available on platforms like GitHub and Hugging Face. The movement has the potential to democratize medical knowledge, driving innovation and improving healthcare globally.
24/07/2024
Members of Katana Labs contributing to important AI Pathology publication in Journal of Pathology Informatics
We are proud to announce that Sarah Schmell and Falk Zakrzewski from Katana Labs have contributed as scientists and authors at University Hospital Dresden to a groundbreaking publication in the Journal of Pathology Informatics: “Joining Forces for Pathology Diagnostics with AI Assistance: The EMPAIA Initiative”. This collaborative effort highlights the transformative role of AI in clinical pathology diagnostics and underscores Katana Labs’ commitment to advancing medical technology.
Major points:
- Platform Development: The EMPAIA initiative has developed a modular, open-source platform that integrates various AI applications to streamline pathology diagnostics.
- Interdisciplinary Collaboration: Bringing together pathologists, AI developers, and industry stakeholders to ensure the platform meets practical clinical needs and regulatory standards.
- Real-world Validation: Extensive testing across 14 pathology labs in Europe and Asia, validating the platform’s effectiveness in diverse clinical settings.
- Standardization and Sustainability: Establishing EMPAIA International to continue the development and advocacy for AI-assisted pathology.
Read the full publication: https://www.sciencedirect.com/science/article/pii/S2153353924000269
08/07/2024
Katana Labs is one of twenty visionary startups in 2024
Katana Labs has been featured in the latest edition of inVISION News eMagazin as one out of 20 visionary startups! Our innovative AI-driven software solutions are set to revolutionize cancer diagnostics. Our flagship product, PAIKON, integrates cloud and AI technology to deliver unparalleled precision and speed in analyzing cancer tissue samples.
Katana Labs is tackling the pressing need for efficient and accurate cancer diagnostics amidst the global hashtag#rise in cancer cases and a shortage of pathologists. With AI, we’re automating histopathological analysis, ensuring timely and reliable results crucial for effective treatment planning.
Read more about our work on pages 32-33 of inVISION eMagazin Startups 2024: https://katalog.tedomedien.de/index.php?catalog=inVISION-eMagazin-Startups-2024-Neu
Link to article: https://invision-news.de/ki-deep-learning/ai-to-fight-cancer/
27/06/2024
IQ Innovation Award in the Life Sciences Cluster for cancer diagnostics with artificial intelligence
In cancer diagnostics, the decision as to whether a cancer is benign or malignant lies in the hands of the pathology department, where the tissue is examined manually using a microscope. However, increasing numbers of cases and a lack of specialist staff are leading to a fatal bottleneck, which the Dresden-based start-up Katana Labs wants to solve with its PAIKON platform: a digital microscope that uses artificial intelligence to analyze millions of tumor cells in a tissue sample in just a few moments. The innovation was awarded the Life Sciences Cluster Prize of the 20th IQ Innovation Award Central Germany at the award ceremony in Merseburg Cathedral on Thursday evening.
“This innovation is a perfect example of how artificial intelligence can help us tackle the major challenges of our time. Staff shortages are not only a problem in the healthcare system, but here they can have dramatic consequences. The Katana Labs platform can process much more information than a human being, relieving the pressure on tight pathology workflows and providing a much broader basis for decision-making in seconds. The founding team is convincing in its claim to revolutionize the diagnosis of the number one widespread disease and also to open up completely new possibilities in research,” said Jörn-Heinrich Tobaben, Managing Director of Metropolregion Mitteldeutschland Management GmbH, explaining the jury’s decision. Endowed with 7,500 euros, the cluster prize was donated by IDT Biologika GmbH.
Official Press release (in German)
Article on 20th IQ Innovation Award (in German)
14/06/2024
Katana Labs' Lead AI: Ernst & Young-Recognized Pioneer Revolutionizing Oncology with AI-Powered Healthcare Innovations"
Katana Labs is revolutionizing oncology with its AI-powered solutions for digital pathology, cancer diagnostics and spatial biology, driving advancements in biomarker development and patient stratification.
Mentioned as relevant biotech startup from Germany in the EYBiotechReport2024, Katana Labs is a shining example of how AI is transforming healthcare.
“Other examples […] are the Dresden-based companies Katana Labs (AI-supported software solutions for image-based cancer diagnostics […].“
“ML for digital pathology and spatial biology to support biomarker development and patient stratification in oncology.“
Report: https://info.ey.com/de-ey-GermanBiotechnologyReport2024-download.html
01/06/2024
Katana Labs' Lead AI Advisor receives a professorship for AI at TU Dresden
We are very pleased for our Lead AI Advisor at Katana Labs Martin Weigert that he has now been appointed professor for machine learning for spatial understanding at the Institute for Artificial Intelligence at Technische Universität Dresden. His research focuses on the exploration of robust and efficient machine learning methods for image-based life science applications with a focus on scalable and problem-adapted methods that enable quantitative extraction of information from large microscopy data. This applies in particular to the recognition, segmentation and tracking of biological objects such as cells, cell nuclei or gene localizations.
Further information: https://www.epfl.ch/labs/weigert-lab and https://tu-dresden.de/ing/informatik/die-fakultaet/news/willkommen-herr-prof-martin-weigert
15/05/2024
State Seceratry Inés Fröhlich visits Katana Labs
We were very pleased about the visit of State Secretary Inés Fröhlich from the Sächsisches Staatsministerium für Wirtschaft, Arbeit und Verkehr to our Katana Labs office. As became clear during the conversation with State Secretary Inés Förhlich, AI is one of the key technologies of the future in Saxony and we at Katana Labs are at the forefront of AI and cancer diagnostics.
30/04/2024
Katana Labs interview
Find out more about our startup Katana Labs in an interview with Startup Mitteldeutschland and about our ambitions to improve the diagnosis of cancer with the help of AI.
Article: https://startup-mitteldeutschland.de/startup-storys/sachsen/katana-labs
25/04/2024
Katana Labs is nominated for IQ innvovation price Germany
We are delighted that our startup Katana Labs has been nominated for the IQ Innovation Award IQ Innovationspreis Mitteldeutschland. Yesterday we pitched our PAIKON product platform, which we want to use to make cancer diagnostics faster and better via AI.
Further information: https://iq-mitteldeutschland.de
19/04/2024
Interview with CEO Falk Zakrzewski on AI and cancer diagnostics
Katana Labs as the AI startup from Saxony, which fights cancer with the help of AI, was interviewed by the MDR MITTELDEUTSCHER RUNDFUNK. See and hear in the interview why I consider it essential that our startup Katana Labs continues to be a model founder for the use of AI against the sunami of cancer.
Interview: https://www.mdr.de/nachrichten/deutschland/video-katana-labs-ki-krebsdiagnostik-100.html
16/04/2024
Prime Minister of Saxony Michael Kretschmer supports Katana Labs
We at Katana Labs are immensely proud that Prime Minister of Saxony Michael Kretschmer supports our work in developing AI for cancer diagnostics and finds our approach as a startup particularly exciting.